Xylyx Bio
New York, US · 1 known investors
Xylyx Bio develops Inspirex bioengineered human organ grafts intended as fully functional, anatomically compatible whole organs for clinical transplantation. The company aims to address the organ transplant shortage and improve access to transplantation, operating in New York.
Investors · 1
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2.1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $297.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $224.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $279.4K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Xylyx Bio do?
- Xylyx Bio develops Inspirex bioengineered human organ grafts intended as fully functional, anatomically compatible whole organs for clinical transplantation. The company aims to address the organ transplant shortage and improve access to transplantation, operating in New York.
- Who are Xylyx Bio's investors?
- Xylyx Bio's investors include Boston Harbor Angels.
- Where is Xylyx Bio headquartered?
- Xylyx Bio is headquartered in New York, US.